RT Journal Article
SR Electronic
T1 Potent human neutralizing antibodies elicited by SARS-CoV-2 infection
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.03.21.990770
DO 10.1101/2020.03.21.990770
A1 Bin Ju
A1 Qi Zhang
A1 Xiangyang Ge
A1 Ruoke Wang
A1 Jiazhen Yu
A1 Sisi Shan
A1 Bing Zhou
A1 Shuo Song
A1 Xian Tang
A1 Jinfang Yu
A1 Jiwan Ge
A1 Jun Lan
A1 Jing Yuan
A1 Haiyan Wang
A1 Juanjuan Zhao
A1 Shuye Zhang
A1 Youchun Wang
A1 Xuanling Shi
A1 Lei Liu
A1 Xinquan Wang
A1 Zheng Zhang
A1 Linqi Zhang
YR 2020
UL http://biorxiv.org/content/early/2020/03/25/2020.03.21.990770.abstract
AB The pandemic caused by emerging coronavirus SARS-CoV-2 presents a serious global public health emergency in urgent need of prophylactic and therapeutic interventions. SARS CoV-2 cellular entry depends on binding between the viral Spike protein receptor-binding domain (RBD) and the angiotensin converting enzyme 2 (ACE2) target cell receptor. Here, we report on the isolation and characterization of 206 RBD-specific monoclonal antibodies (mAbs) derived from single B cells of eight SARS-CoV-2 infected individuals. These mAbs come from diverse families of antibody heavy and light chains without apparent enrichment for particular families in the repertoire. In samples from one patient selected for further analyses, we found coexistence of germline and germline divergent clones. Both clone types demonstrated impressive binding and neutralizing activity against pseudovirus and live SARS-CoV-2. However, the antibody neutralizing potency is determined by competition with ACE2 receptor for RBD binding. Surprisingly, none of the SARS CoV 2 antibodies nor the infected plasma cross-reacted with RBDs from either SARS CoV or MERS CoV although substantial plasma cross reactivity to the trimeric Spike proteins from SARS-CoV and MERS-CoV was found. These results suggest that antibody response to RBDs is viral species-specific while that cross-recognition target regions outside the RBD. The specificity and neutralizing characteristics of this plasma cross-reactivity requires further investigation. Nevertheless, the diverse and potent neutralizing antibodies identified here are promising candidates for prophylactic and therapeutic SARS-CoV-2 interventions.